NASDAQ:TOCA - Tocagen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.49 -0.06 (-11.00 %) (As of 02/20/2020 06:12 AM ET) Add Compare Today's Range$0.46Now: $0.49▼$0.5450-Day Range$0.46MA: $0.53▼$0.6152-Week Range$0.42Now: $0.49▼$12.00Volume620,391 shsAverage Volume457,116 shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/ABeta3.78 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TOCA Previous Symbol CUSIPN/A CIK1419041 Webhttp://www.tocagen.com/ Phone858-412-8400Debt Debt-to-Equity Ratio0.46 Current Ratio1.43 Quick Ratio1.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.04 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book0.17Profitability EPS (Most Recent Fiscal Year)($2.44) Net Income$-48,960,000.00 Net Margins-201,488.91% Return on Equity-182.15% Return on Assets-82.01%Miscellaneous Employees77 Outstanding Shares23,898,000Market Cap$11.60 million Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive TOCA News and Ratings via Email Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TOCA Rates by TradingView Tocagen (NASDAQ:TOCA) Frequently Asked Questions What is Tocagen's stock symbol? Tocagen trades on the NASDAQ under the ticker symbol "TOCA." How were Tocagen's earnings last quarter? Tocagen Inc (NASDAQ:TOCA) issued its earnings results on Tuesday, November, 12th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.10. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Tocagen had a negative net margin of 201,488.91% and a negative return on equity of 182.15%. View Tocagen's Earnings History. When is Tocagen's next earnings date? Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Tocagen. What price target have analysts set for TOCA? 9 brokerages have issued 12-month target prices for Tocagen's shares. Their forecasts range from $1.00 to $28.00. On average, they expect Tocagen's stock price to reach $8.22 in the next year. This suggests a possible upside of 1,593.8% from the stock's current price. View Analyst Price Targets for Tocagen. What is the consensus analysts' recommendation for Tocagen? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen. What are Wall Street analysts saying about Tocagen stock? Here are some recent quotes from research analysts about Tocagen stock: 1. According to Zacks Investment Research, "Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. " (1/15/2020) 2. HC Wainwright analysts commented, "We lower our rating of TOCA to and considering the limited visibility of company’s pipeline development strategy going forward, we are not comfortable to determine a specific price target. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property. Tocagen, Inc. September 12, 2019 H.C. WAINWRIGHT & CO." (9/12/2019) Has Tocagen been receiving favorable news coverage? News coverage about TOCA stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tocagen earned a media sentiment score of -4.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Tocagen. Are investors shorting Tocagen? Tocagen saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 2,020,000 shares, a decrease of 14.4% from the December 31st total of 2,360,000 shares. Based on an average daily trading volume, of 533,200 shares, the short-interest ratio is currently 3.8 days. Approximately 9.2% of the company's shares are short sold. View Tocagen's Current Options Chain. Who are some of Tocagen's key competitors? Some companies that are related to Tocagen include Bellerophon Therapeutics (BLPH), Merrimack Pharmaceuticals (MACK), Pharmaxis (PXSLY), Annovis Bio (ANVS), Iterum Therapeutics (ITRM), Moleculin Biotech (MBRX), Evoke Pharma (EVOK), Jaguar Health (JAGX), RegeneRx Biopharmaceuticals (RGRX), Pulmatrix (PULM), Generex Biotechnology (GNBT), Edesa Biotech (EDSA), Addex Therapeutics (ADDXF), Akari Therapeutics (AKTX) and Vistagen Therapeutics (VTGN). What other stocks do shareholders of Tocagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Agile Therapeutics (AGRX), Catalyst Pharmaceuticals (CPRX), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), Marinus Pharmaceuticals (MRNS), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). Who are Tocagen's key executives? Tocagen's management team includes the folowing people: Mr. Martin J. Duvall, CEO & Director (Age 57)Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66) When did Tocagen IPO? (TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO. Who are Tocagen's major shareholders? Tocagen's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (2.24%), Acadian Asset Management LLC (0.90%) and Goldman Sachs Group Inc. (0.20%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Institutional Ownership Trends for Tocagen. Which major investors are selling Tocagen stock? TOCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Tocagen. Which major investors are buying Tocagen stock? TOCA stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Insider Buying and Selling for Tocagen. How do I buy shares of Tocagen? Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Tocagen's stock price today? One share of TOCA stock can currently be purchased for approximately $0.49. How big of a company is Tocagen? Tocagen has a market capitalization of $11.60 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen. What is Tocagen's official website? The official website for Tocagen is http://www.tocagen.com/. How can I contact Tocagen? Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected] MarketBeat Community Rating for Tocagen (NASDAQ TOCA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 226 (Vote Outperform)Underperform Votes: 234 (Vote Underperform)Total Votes: 460MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: What does the Producer Price Index (PPI) tell investors?
